Shandong Boan Biotechnology Co., Ltd. (HKG:6955)
Hong Kong · Delayed Price · Currency is HKD 6.66
-0.17 (-2.49%)
At close: May 7, 2026
HKG:6955 Revenue
In the year 2025, Shandong Boan Biotechnology had annual revenue of 784.82M CNY with 8.06% growth. Shandong Boan Biotechnology had revenue of 391.41M in the half year ending December 31, 2025, with 9.67% growth.
Revenue
784.82M CNY
Revenue Growth
+8.06%
P/S Ratio
4.75
Revenue / Employee
1.10M CNY
Employees
714
Market Cap
4.14B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 784.82M | 58.51M | 8.06% |
| Dec 31, 2024 | 726.32M | 108.19M | 17.50% |
| Dec 31, 2023 | 618.13M | 102.17M | 19.80% |
| Dec 31, 2022 | 515.96M | 357.26M | 225.11% |
| Dec 31, 2021 | 158.70M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Viva Biotech Holdings | 1.92B |
| Qyuns Therapeutics | 897.99M |
| BioDlink International Company | 831.99M |
| Medtide | 634.40M |
| Mirxes Holding Company | 166.32M |
| Antengene Corporation | 117.22M |
| Jacobio Pharmaceuticals Group | 59.56M |
| Jiangsu Recbio Technology | 14.16M |